ESMO 2023 | Doxorubicin with zalifrelimab and balstilimab in soft tissue sarcomas

Breelyn Wilky, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, comments on results from a Phase II trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas (STS) (NCT04028063). Combing chemotherapy with immune checkpoint inhibitors resulted in meaningful improvements in 6 month progression-free survival in patients, especially those who do not respond to monotherapy. This interview took place at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting in Dublin, Ireland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.